Bal Pharma Limited (NSE:BALPHARMA)

Market Cap	1.30B -21.9%
Revenue (ttm)	3.09B -2.0%
Net Income	81.23M +12.0%
EPS	5.06 +8.5%
Shares Out	n/a
PE Ratio	16.06
Forward PE	n/a
Dividend	1.20 (1.42%)
Ex-Dividend Date	Sep 18, 2025

Volume	9,668
Average Volume	21,701
Open	84.60
Previous Close	85.13
Day's Range	81.11 - 85.23
52-Week Range	60.00 - 111.18
Beta	0.40
RSI	57.33
Earnings Date	May 27, 2026

About Bal Pharma

Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic p...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1987
• Employees: 986
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: BALPHARMA

Financial Performance

In fiscal year 2025, Bal Pharma's revenue was 3.03 billion, a decrease of -10.65% compared to the previous year's 3.39 billion. Earnings were 72.15 million, a decrease of -2.39%.